Brain chemical finding could open door to new schizophrenia drugs

September 30, 2010

New research has linked psychosis with an abnormal relationship between two signalling chemicals in the brain. The findings, published in tomorrow's edition of the journal Biological Psychiatry, suggest a new approach to preventing psychotic symptoms, which could lead to better drugs for schizophrenia.

Schizophrenia is one of the most common severe mental health conditions. Sufferers experience symptoms of psychosis - an inability to distinguish between reality and imagination - such as and delusions. The condition tends to begin in the late teens or twenties, and usually persists for the rest of the sufferer's life.

Brain chemicals called neurotransmitters carry signals from one nerve cell to another. Research has linked schizophrenia with abnormally high levels of a called dopamine in a region of the brain called the striatum. Drugs currently used to treat schizophrenia block the effects of dopamine in the brain. These drugs are not effective for all patients, and can have serious side effects.

The new pilot research, funded by the Medical Research Council (MRC), provides evidence that high levels of dopamine in people with occur as a consequence of changes in another , glutamate. Glutamate-releasing cells in a brain region called the hippocampus connect to the striatum and influence the activity of dopamine-releasing cells. Drugs that interfere with glutamate signals in the brain might therefore be able to prevent psychotic symptoms in people with schizophrenia.

"Schizophrenia is a devastating illness that destroys the lives of people who are afflicted and those around them," said Dr James Stone of the Department of Medicine at Imperial College London, first author of the study. "At the moment, the drugs we have just aren't adequate. They don't help everybody, and they don't stop some of the most debilitating symptoms."

The researchers carried out brain scans on 16 people with an at-risk mental state for psychosis and 12 healthy volunteers, to measure the levels of glutamate and dopamine. In people with early signs of psychotic symptoms, there was a negative correlation between glutamate levels in the hippocampus and dopamine levels in the striatum area. There was a particularly marked correlation in the subjects who went on to develop psychosis later. There was no correlation in the healthy subjects.

"In healthy volunteers, there's no clear relationship between glutamate and dopamine, but in people with early signs of psychosis, we see this abnormal relationship," Dr Stone said. "This suggests that the signalling pathway between the and the striatum is dysfunctional, and we might be able to treat this by targeting the glutamate system. If drugs that act on glutamate signalling can prevent psychotic symptoms, it would mean a real shift in the way that people are treated for schizophrenia.

"The next step will be to see if these results are confirmed in a larger group of people. There are already a number of promising drug candidates that interfere with glutamate signalling, so hopefully in a few years we'll be able to start testing new treatments for people with schizophrenia."

Professor Chris Kennard, chair of the MRC Neuroscience and Mental Health Board, said:

"Studies like these are helping to unravel the complex mechanisms of psychiatric illness and bring us a step closer to more effective, targeted drugs for patients with schizophrenia. The MRC funds research like this in order to bring scientific findings from the lab bench to patient bedside, more quickly. If we can develop new drugs that prevent psychotic symptoms, it would mean a real benefit for patients with ."

More information: J.M. Stone et al. "Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis." Biological Psychiatry, 1 October 2010.

Related Stories

Recommended for you

Your mood depends on the food you eat, and what you should eat changes as you get older

December 11, 2017
Diet and dietary practices differentially affect mental health in young adults versus older adults, according to new research from Binghamton University, State University of New York.

Certain books can increase infant learning during shared reading, study shows

December 11, 2017
Parents and pediatricians know that reading to infants is a good thing, but new research shows reading books that clearly name and label people and objects is even better.

Twitter can reveal our shared mood

December 11, 2017
In the largest study of its kind, researchers from the University of Bristol have analysed mood indicators in text from 800 million anonymous messages posted on Twitter. These tweets were found to reflect strong patterns ...

Infant brain responses predict reading speed in secondary school

December 11, 2017
A study conducted at the Department of Psychology at the University of Jyväskylä, Finland and Jyväskylä Centre for Interdisciplinary Brain Research (CIBR) has found that the brain responses of infants with an inherited ...

Many different types of anxiety and depression exist, new study finds

December 8, 2017
Five new categories of mental illness that cut across the current more broad diagnoses of anxiety and depression have been identified by researchers in a Stanford-led study.

Study sheds light on the voices in our head

December 8, 2017
New research showing that talking to ourselves in our heads may be the same as speaking our thoughts out loud could help explain why people with mental illnesses such as schizophrenia hear voices.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

16180339887
not rated yet Sep 30, 2010
Glutamate..any possible connection to the continued prevalence of MSG in foods?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.